Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone

@article{Damiani2016PathwaysOC,
  title={Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone},
  author={Roberto Marques Damiani and Dinara Moura and Cassiana Macagnan Viau and Rafael A. Caceres and Jo{\~a}o Antonio P{\^e}gas Henriques and Jenifer Saffi},
  journal={Archives of Toxicology},
  year={2016},
  volume={90},
  pages={2063-2076}
}
Anthracyclines, e.g., doxorubicin (DOX), and anthracenediones, e.g., mitoxantrone (MTX), are drugs used in the chemotherapy of several cancer types, including solid and non-solid malignancies such as breast cancer, leukemia, lymphomas, and sarcomas. Although they are effective in tumor therapy, treatment with these two drugs may lead to side effects such as arrhythmia and heart failure. At the same clinically equivalent dose, MTX causes slightly reduced cardiotoxicity compared with DOX. These… CONTINUE READING